These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28847261)

  • 1. [61 SEFH Congress; Outstanding Clinical Cases (second part)].
    Jefe E
    Farm Hosp; 2017 Sep; 41(5):651-658. PubMed ID: 28847261
    [No Abstract]   [Full Text] [Related]  

  • 2. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?
    Chin CJ
    Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].
    Rohrmeier C; Kühnel TS
    HNO; 2012 Nov; 60(11):1003-6. PubMed ID: 22706563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
    Simonds J; Miller F; Mandel J; Davidson TM
    Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of estrogen in treatment of familial hemorrhagic telangiectasia.
    Harrison DF
    Laryngoscope; 1982 Mar; 92(3):314-20. PubMed ID: 7040867
    [No Abstract]   [Full Text] [Related]  

  • 9. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tranexamic acid and bevacizumab in hereditary hemorrhagic telangiectasia patients presenting with epistaxis.
    Lacout A; Marcy PY; El Hajjam M; Lacombe P
    Cutis; 2013 Apr; 91(4):173-4. PubMed ID: 23763075
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.
    Yaniv E; Preis M; Shevro J; Nageris B; Hadar T
    Rhinology; 2011 Jun; 49(2):214-6. PubMed ID: 21743879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary hemorrhagic telangiectasia/avastin.
    Davidson TM; Olitsky SE; Wei JL
    Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking thalidomide out of rehab.
    Akhurst RJ
    Nat Med; 2010 Apr; 16(4):370-2. PubMed ID: 20376039
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.
    Flanagan BA; Collins C; Parra S
    Cutis; 2012 Feb; 89(2):69-72. PubMed ID: 22474728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Sabbà C; Gallitelli M; Palasciano G
    N Engl J Med; 2001 Sep; 345(12):926. PubMed ID: 11565536
    [No Abstract]   [Full Text] [Related]  

  • 18. Endoscopic-guided coblation treatment of nasal telangiectasias in hereditary hemorrhagic telangiectasia: "How I do it".
    Poetker DM
    Am J Rhinol Allergy; 2017 May; 31(3):205-206. PubMed ID: 28490409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
    Alderman C; Corlett J; Cullis J
    Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440
    [No Abstract]   [Full Text] [Related]  

  • 20. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
    Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
    Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.